In this section : Covid-19
Molnupiravir
Sotrovimab
Conscious Proning
Covid-19 Basics
Remdesivir
Thromboprophylaxis
Identifying Patients in the Highest Risk Groups
Steroids for Patients with Covid-19 Infection
IL-6 Inhibitors – Tocilizumab or Sarilumab
Baricitinib
Paxlovid (Nirmatrelvir/Ritonavir)
Covid-19 Sick Day Rules for Patients with Primary Adrenal Insufficiency
Molnupiravir
Last updated 27th June 2023
Introduction
- Molnupiravir is not a first line choice for patients with COVID-19 infection. Please discuss with relevant consultant and pharmacist before prescribing.
- Molnupiravir may be considered for use in patients with COVID-19 not requiring oxygen, who are either in a high risk group or who have been identified as at risk of destabilisation of their current condition due to their COVID-19 infection.
- Discuss during the working day with relevant consultant and pharmacist if the following criteria are met:
- Within 5 days of symptom onset
- Ritonavir & nirmatrelvir NOT suitable
- Sotrovimab NOT suitable
- Remdesivir NOT suitable
Dose
The dose of molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days.
Availability
Available from pharmacy between 9am and 5pm.
Links
- NICE COVID-19 rapid guideline: Managing COVID-19
- SEHD Covid Therapeutic Alert 2023 1 – Publication of NICE Multiple Technology Appraisal (MTA) – Treatment Recommendations for Covid 19
- Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Content by Alison Moore